BioSpace News Archive

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral presentations and two posters) will be presented at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America (“SMSNA”), to take place October 24-27th 2019 in Nashville, TN.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled “A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies.”

Sagentia, the global product development and technology consultancy and a Science Group company, announces the launch of MediTheatre, its Virtual Reality ‘showroom’. Delegates at The MedTech Conference in Boston on September 23rd-25th, will be the first to interact with Sagentia-developed medical technology products through this new custom developed VR facility.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was awarded Honorable Distinction at the 2019 SOHO (Society of Hematologic Oncology) Annual Meeting.

Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, received clearance from the Food and Drug Administration (FDA) for PhoenixMD’s Investigational New Drug (IND) application for its proprietary PMD-026.

Healthy Alliance Independent Practice Association (IPA), Innovative Health Alliance of New York, LLC (IHANY), and Fidelis Care are partnering to provide critical funding and careful coordination of services to Medicaid members insured by Fidelis Care.

Eleusis, a clinical stage life science company established to develop the therapeutic potential of serotonin 2A receptor (5-HT2A) agonists, also known as psychedelics, today announced the appointment of David Guyer, M.D., to its Board of Directors, effective December 15, 2019.

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces that an abstract from its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of AG013 in severe oral mucositis, will be presented as a poster at the upcoming European Society of Medical Oncology Congress (“ESMO”) on September 27 – October 1, 2019, in Barcelona, Spain,.

arian (NYSE: VAR) today announced the United States Trade Representative (USTR) has granted exclusion of components sourced from China for linear accelerators manufactured in the U.S from Section 301 tariffs.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from a study showing positive impact of the Company’s SkinTE™ skin regeneration product on a broad range of cases, demonstrating progressive wound closure including coverage of exposed underlying structures such as bone and tendon.